Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.47 |
| ▸ | PPARG | P37231 | 12/20 | 0.47 |
| ▸ | RXRB | P28702 | 6/20 | 0.46 |
| ▸ | RXRG | P48443 | 6/20 | 0.46 |
| ▸ | RARA | P10276 | 5/20 | 0.46 |
| ▸ | RARB | P10826 | 5/20 | 0.46 |
| ▸ | RARG | P13631 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14203397 | 0.80 | RXRA (0.49) | RXRAPPARGRXRBRXRGRARA | |
| SCHEMBL4863528 | 0.79 | RXRA (0.46) | RXRAPPARGRXRBRXRGRARA | |
| SCHEMBL6705749 | 0.77 | RXRA (0.67) | RXRAPPARGRXRBRXRGRARA | |
| SCHEMBL6705747 | 0.77 | RXRA (0.67) | RXRAPPARGRXRBRXRGRARA | |
| SCHEMBL4862938 | 0.76 | RXRA (0.46) | RXRAPPARGRXRBRXRGRARA | |
| SCHEMBL6838138 | 0.74 | RARG (0.39) | RXRAPPARGRARGCYP3A4TSHR | |
| SCHEMBL6706973 | 0.74 | RXRA (0.42) | RXRAPPARGRXRBRXRGRARA | |
| SCHEMBL6833506 | 0.73 | RXRA (0.61) | RXRAPPARGRXRBRXRGRARA | |
| SCHEMBL6707048 | 0.72 | RXRA (0.70) | RXRAPPARGRXRBRXRGRARA | |
| SCHEMBL6706020 | 0.72 | RXRA (0.61) | RXRAPPARGRXRBRXRGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1373240-B1 | RETINOID X RECEPTOR MODULATORS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040248919-A1 | Fluorinated trienes and their use as rxr modulators | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| US-20040167160-A1 | Retinoid x receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| EP-1373240-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1368296-A1 | FLUORINATED TRIENES AND THEIR USE AS RXR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002071827-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002072528-A1 | FLUORINATED TRIENES AND THEIR USE AS RXR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167160-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | RXRA 1/4885PPARG 18/4885RXRB 3/4885 |
| US-20040248919-A1 | Fluorinated trienes and their use as rxr modulators | RXRA, THRA, RXRB | RXRA 1/4885PPARG 20/4885RXRB 3/4885 |
| US-20080090860-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | RXRA 1/4885PPARG 19/4885RXRB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.